AiCure

Global News

Merck, NewLink Genetics collaborate on investigational Ebola vaccine

Wednesday, November 26, 2014 11:54 AM

Merck and Ames, Iowa-based NewLink Genetics have entered into an exclusive worldwide license agreement to research, develop, manufacture and distribute NewLink’s investigational rVSV-EBOV (Ebola) vaccine candidate.

More... »


Report: AML treatment market to witness modest growth by 2020

Wednesday, November 26, 2014 11:53 AM

The value of the global acute myeloid leukemia (AML) therapeutics market will increase moderately from $632.6 million in 2013 to $878.6 million by 2020, representing a Compound Annual Growth Rate (CAGR) of 4.8%, according to New York-based business intelligence provider GBI Research.

More... »


Global Ebola relief effort not reaching rural communities

Wednesday, November 26, 2014 11:50 AM

Unprecedented levels of donation to support Ebola-struck Sierra Leone are bypassing many of the places where funding is urgently needed, claim two U.K.-based experts. The independent experts, Dutch sustainability scientist Robert Verkerk, Ph.D., and Sierra Leonean crisis management expert Morris Marah, have just returned from a one-week capacity assessment mission requested by Hon Alpha Kanu, Minister of Information and Communications of Sierra Leone.

More... »

Yabao Pharmaceuticals, MRC Technology partner in China

Wednesday, November 26, 2014 11:49 AM

China-based Yabao Pharmaceutical has inked an exclusive license with MRC Technology, a U.K. medical research charity, to discover, develop and commercialize innovative products targeting a kinase target for neurodegeneration for the treatment of Parkinson's disease.

More... »

CDISC, TransCelerate release new standards for diabetes, cardiovascular disease

Wednesday, November 26, 2014 11:45 AM

The Clinical Data Interchange Standards Consortium (CDISC), a global nonprofit, and King of Prussia, Pa.-based nonprofit TransCelerate BioPharma have made available therapeutic area standards for diabetes and cardiovascular (CV) disease areas through the Coalition for Accelerating Standards and Therapies (CFAST), a joint initiative of CDISC and the Critical Path Institute (C-Path).

More... »

BioMarin to acquire Prosensa for $680M

Tuesday, November 25, 2014 08:30 AM

BioMarin Pharmaceutical, based in San Rafael, Calif., will acquire Prosensa for $17.75 per share, for a total up-front consideration of approximately $680 million. In addition, two approximately $80 million contingent milestones are payable for the approval of drisapersen in the U.S. no later than May 15, 2016, and Europe no later than Feb. 15, 2017, respectively.

More... »

SEC suspends trading in companies touting Ebola-related prevention/treatment operations

Monday, November 24, 2014 02:49 PM

The Securities and Exchange Commission has suspended trading in four companies that claim to be developing products or services in response to the Ebola outbreak, citing a lack of publicly available information about the companies' operations.

More... »

Gates Foundation to support Ebola-affected countries, accelerate treatment evaluation

Monday, November 24, 2014 02:46 PM

The Bill & Melinda Gates Foundation, based in Seattle, Wash., will be supporting efforts in Guinea and other Ebola-affected countries to scale up the production and evaluation of convalescent plasma and other convalescent blood products as potential therapies for people infected with the Ebola virus. Various drug candidates also will be evaluated, including the experimental antiviral drug brincidofovir.

More... »

Almac, ESMS Global collaborate

Monday, November 24, 2014 02:45 PM

Almac, a global provider of advanced clinical technology and support services, and ESMS, a 24/7 medical emergency response service for clinical trials based in the U.K., are collaborating to offer clients an exclusive solution surrounding emergency unblinding procedures.

More... »

AstraZeneca to expand its Maryland biologics manufacturing center, add 300 jobs

Monday, November 24, 2014 02:44 PM

AstraZeneca plans to expand its biologics manufacturing center in Frederick, Md. The more than $200 million project will increase production capacity at the facility to support AZ’s maturing pipeline, and will help the company keep pace with a growing demand for the development and use of biologics, which currently represent nearly 50% of AZ’s overall pipeline.

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs